Researchers at the University of Illinois Chicago are working with the National Institutes of Health and University of Minnesota to establish a center for antiviral drug development for pandemic-level viruses, including Ebola and SARS-CoV-2.
In a new study, researchers show how a critical Lassa virus protein, called polymerase, drives infection by harnessing a cellular protein in human hosts. Their work suggests future therapies could target this interaction to treat patients.
Helical nucleocapsids in infected cells are composed of Marburg viral genomic RNA and nucleoproteins, or NPs, that are structurally similar to those of the Ebola virus. Future drug development may be possible based on the targeting of nucleocapsid formation, which may inhibit the Marburg virus' ability to replicate.
A new tool can quickly and reliably identify the presence of Ebola virus in blood samples, according to a study by researchers at Washington University School of Medicine in St. Louis and colleagues at other institutions.
The team's latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.
A new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSVΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo (DRC) that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.
The study is the first published research examining post–Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will help inform health officials’ approach to vaccine use for outbreak control, the researchers said.
• Researchers have identified a set of receptors shared across human, mosquito, and other animal cells for the eastern equine encephalitis virus (EEEV) and two related viruses, a crucial first step for developing preventive and curative treatments.
• In experiments with cells and mouse models with a related virus, the scientists were able to prevent infection and disease progression using decoy molecules to hamper viral entry into cells.
• In a 2019 outbreak of eastern equine encephalitis (EEE, or triple E) in New England, 30 percent of infected people died and half of those who survived had long-term neurologic damage.
• Done between major outbreaks, this type of research into highly pathogenic viruses with pandemic potential can help improve preparedness for future outbreaks.
A nationwide team of researchers, led by scientists at University of Utah Health and The Rockefeller University, has determined how a genetic mutation found in mice and monkeys interferes with viruses such as HIV and Ebola. They say the finding could eventually lead to the development of medical interventions in humans.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
The Global Virus Network (GVN), representing 63 Centers of Excellence and 11 Affiliates in 34 countries comprising foremost experts in every class of virus causing disease in humans, and the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation [Institute for Health Research, Epidemiological Surveillance and Training], or the IRESSEF, announced the addition of the IRESSEF as GVN’s newest Center of Excellence.
Mount Sinai researchers have uncovered the complex cellular mechanisms of Ebola virus, which could help explain its severe toll on humans and identify potential pathways to treatment and prevention. In a study published in mBio, the team reported how a protein of the Ebola virus, VP24, interacts with the double-layered membrane of the cell nucleus (known as the nuclear envelope), leading to significant damage to cells along with virus replication and the propagation of disease.
Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus. Olena Shtanko, Ph.D., a Staff Scientist at the Texas Biomedical Research Institute (Texas Biomed), has received more than $1 million from the National Institutes of Health (NIH) to explore different aspects of Ebola virus infection.
Researchers are developing a new sensor that can detect Ebola in a single drop of blood and provides results in just an hour. With further development, the technology might also enable fast and inexpensive detection of other viruses, including the virus that causes COVID-19.
In a new Cell Reports study, researchers at La Jolla Institute for Immunology demonstrate how Ebola virus has found a different way to get things done. The virus encodes only eight proteins but requires dozens of functions in its lifecycle. The new study shows how one of Ebola virus’s key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs.
A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.
Researchers have identified a previously unknown site on the filovirus glycoprotein to which small drug molecules can bind and prevent infection -- blocking both sites may be more a more effective treatment with reduced risk of side effects.
As the world grapples with COVID-19, the Ebola virus is again raging. A research team at University of Delaware is using supercomputers to simulate the inner workings of Ebola (as well as COVID-19), looking at how molecules move, atom by atom, to carry out their functions. Now, they have revealed structural features of the Ebola virus’s protein shell to provide therapeutic targets to destabilize the virus and knock it out with an antiviral treatment.
Scientists at the University of Delaware report a computational study of a nucleocapsid found in the Ebola virus and show that the binding of the ssRNA allows the nucleocapsid to maintain its shape and structural integrity.
Even after heroic medical and societal efforts finally break the back of the current COVID-19 pandemic, the global sigh of relief may not last long. The chilling reality is that viral threats are growing more common. And they’re getting deadlier.
Global health scholars have issued a clarion call about the needless loss of life expected because of a foreseeable prospect of “slow and inadequate access to supplies” to control COVID-19 in sub-Saharan Africa. They say what is unfolding now is similar to when lifesaving diagnostics and treatments came to the region long after they were available elsewhere.
Each year since 2008, SCT has awarded the David Sackett Trial of the Year Award to a randomized, controlled trial published (either electronically or in print) in the previous calendar year. The 2020 recipient is Pamoja Tulinde Maisha (PALM [“Together Save Lives”] in the Kiswahili language) trial.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
After the Ebola virus tore through western Africa in 2015, two UC Santa Barbara researchers studied the xenophobia of the disease generated among people who had almost zero chance of being infected by it.
A group of University of Alberta researchers who have discovered why the drug remdesivir is effective in treating the coronaviruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) expect it might also be effective for treating patients infected with the new COVID-19 strain.
Interacting contagious diseases like influenza and pneumonia—and perhaps coronavirus too—follow the same complex spreading patterns as social trends, like the adoption of new slang or technologies. This new finding, published in Nature Physics, could lead to better tracking and intervention when multiple diseases spread through a population at the same time.
Robert Stahelin studies some of the world’s deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates. Stahelin, professor at Purdue University, examines how these viruses take advantage of human host cells.
Scientists using specialized beamlines at Argonne's Structural Biology Center (SBC), a facility for macromolecular crystallography at the Advanced Photon Source, derived insights that led to the discovery of a promising new drug for Ebola.
La Jolla Institute for Immunology (LJI) is placing their confidence in Berkeley Lights’ Beacon® Optofluidic Platform and B cell antibody discovery workflow to accelerate the discovery of rare and lifesaving antibodies for the treatment of re-emerging and emerging diseases.
In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).
WCS (Wildlife Conservation Society) and NIH (National Institutes of Health) scientists partnered with the Republic of Congo Ministry of Health to develop a low-cost educational outreach program and surveillance system for wildlife mortality that has continued now for over a decade.
Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly
The World Health Organization’s declaration today that the year-long Ebola crisis is a Public Health Emergency of International Concern is hoped to raise much-needed awareness and resources for preparedness and control efforts across the region. The decision was made following new incidents highlighting risks of repeated cross-border spread of the ongoing Ebola outbreak in the Democratic Republic of Congo.
A new risk assessment model for the transmission of Ebola accurately predicted its spread into the Republic of Uganda, according to the Kansas State University researchers who developed it. They published "Risk assessment of Ebola virus disease spreading in Uganda using a multilayer temporal network" in bioRxiv before the Uganda cases.